ClinicalTrials.gg
Not yet recruitingNCT07001787Updated Jun 3, 2025

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10510 in Healthy Subjects

A Phase 1 interventional study of Drug:HS-10510; and Drug:Placebo in Dyslipidemia, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-03.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of HS-10510 following single and multiple dose administration to healthy subjects with or without elevated Low-Density Lipoprotein-Cholesterol (LDL-C) levels.

This study will consist of three parts (Parts A,B and C). 32 subjects have been planned for Part A and up to 36 subjects for Part B and 20 subjects for Part C.

Read the detailed description

This is a Phase I, First In Human (FIH), randomized, double-blind, placebo-controlled, study in Chinese healthy male and female subjects at one center. 32 subjects have been planned for Part A and up to 36 subjects for Part B and 20 subjects for Part C.

  • Part A(SAD cohort): A Screening Period of maximum 28 days. Admission to study center (Day -1). A Treatment Period (Day 1 to Day 4) with a single dose of HS-10510 or placebo on Day 1. Subjects will be discharged on Day 4. A Follow-up Visit within 7 days after the Investigational Medicinal Product (IMP) dose for all cohorts. (i) Part A1 - Up to 4 dose cohorts of HS-10510 are planned to be investigated. Within each cohort, 6 subjects will be randomized to receive HS-10510, and 2 subjects randomized to receive placebo. (ii) Part A2 - The subjects from a chosen cohort in Part A1 will stay at study center for 7 days to wash out after the first dose administration of IMP and will receive HS-10510 or placebo after intake of a high-calorie, high-fat breakfast, to assess the effect of food on the PK of HS-10510. The subjects will stay at the study center until 72 hours post-dose in both the parts.
  • Part B(MAD cohort): Up to 3 dose cohorts are planned to be investigated. In each cohort, 12 subjects will participate and receive either HS-10510 or placebo, randomized 3:1 for 28 days dosing.
  • Part C(Rosuvastatin MAD cohorts):20 subjects in this cohort will receive either HS-10510 in combination with rosuvastatin (10 subjects) or placebo in combination with rosuvastatin (10 subjects). Subjects eligible for these cohorts will begin a Screening period of 28 days, a rosuvastatin run-in period of 28 days, Treatment period of 28 days for this cohort and one Follow-up visits (1 week after last dose of IMP).
02

Conditions studied

  • Dyslipidemia

Browse trials for

Keywords

  • Elevated LDL-C;Hypercholesterolemia
03

In context

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

This study's planned enrollment of 88 is below the median of 100 across 986 interventional studies indexed under Dyslipidemias.

Browse Dyslipidemias studies →

Lead sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd. is the lead sponsor of 138 studies on the registry; 72 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female subjects aged 18-55 years (inclusive) at the time of signing the form.
  2. Agree to use highly effective from the date of signing the informed consent to 30 days after the last dose.
  3. Male or female subjects agree to avoid donating sperm or eggs from the date of signing the informed consent to 90 days after the last dose.
  4. Female subjects of must have a negative blood pregnancy test within 3 days before dosing.
  5. Based on the medical history, physical examination, vital signs (VS) measurements, and and safety test results conducted during the screening visit and before randomization, the subject is in good health.
  6. The subject has a full understanding of the trial content, process, and potential adverse reactions, is willing to strictly adhere to the trial protocol to complete this study, and voluntarily signs the informed consent form.
  7. No more than 14 units of alcohol (1 unit = 285 mL of beer, 25 mL of spirits, 125 mL of wine) in a single session within two weeks before screening; no alcohol (including alcohol-containing products) 48 hours before dosing and throughout the study period.
  8. No smoking 48 hours before dosing and throughout the study period.
  9. No more than 6 cups (approximately 250 mL per cup) of coffee, tea, cola, or other caffeine-containing beverages on average per day within three months before screening; no xanthine- or caffeine-containing foods or beverages throughout the study period.
  10. Maintain a stable diet and exercise lifestyle throughout the study period; avoid all activities that may cause injury or intense physical activity.
  11. Agree to avoid consuming grapefruit, grapefruit juice, bitter orange, bitter orange juice, or other products containing grapefruit or bitter orange, mulberry juice, cruciferous vegetables (such as kale, watercress, Chinese broccoli, Brussels sprouts, and mustard greens), or grilled meats from 7 days before dosing to the end of the last visit.

    For Part A

  12. between 19.0-28.0 kg/m2 (inclusive), with a minimum weight of 50.0 kg for males and 45.0 kg for females.

    For Part B

  13. Fasting LDL-C between 1.8-4.9 mmol/L (inclusive) at screening.
  14. Fasting triglycerides ≤4.52 mmol/L at screening.
  15. BMI between 20.0-35.0 kg/m2 (inclusive), with a minimum weight of 50.0 kg for males and 45.0 kg for females.

    For Part C

  16. Fasting LDL-C between 2.6-4.9 mmol/L (inclusive) at screening.
  17. Fasting triglycerides ≤4.52 mmol/L at screening.
  18. BMI between 20.0-35.0 kg/m2 (inclusive), with a minimum weight of 50.0 kg for males and 45.0 kg for females.
  19. LDL-C reduction of ≥30% after a 28-day rosuvastatin run-in period.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with abnormalities in vital signs, physical examination, or laboratory test results during the screening period, as determined by the investigator (a single retest may be performed within the screening window if there is a clear reason for retesting, and the retest results will be used for screening).
  2. Subjects who have undergone LDL apheresis or plasmapheresis within 12 months before screening.
  3. Subjects who have donated or lost ≥400 mL of blood or received a blood transfusion or bone marrow donation within 3 months before screening; or donated or lost ≥200 mL of blood within 1 month before screening.
  4. Subjects with clinically significant abnormalities in 12-lead results at screening, as determined by the investigator (e.g., interval (Fridericia's formula) >450 msec for males, >470 msec for females; PR interval >200 msec, etc.).
  5. Subjects with systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg at screening.
  6. Subjects with (ALT) >1.5×, aspartate aminotransferase (AST) >1.5×ULN, or total (TBIL) >1×ULN at screening.
  7. Pregnant or breastfeeding females.
  8. Subjects who have undergone major surgery within 3 months before screening or plan to undergo surgery during the study period.
  9. Subjects who are positive for surface antigen (HBsAg), antibody (HCV-Ab), antibody (HIV-Ab), or syphilis serospecific antibody (TP-Ab).
  10. Subjects who are heavy smokers or have smoked an average of 5 or more cigarettes per day within 3 months before screening.
  11. Subjects with difficulty in venous blood collection or who experience fainting or dizziness during blood collection.
  12. Subjects who have taken any medication, including prescription drugs, over-the-counter drugs, herbal medicines, or dietary supplements, within 2 weeks or 5 half-lives (whichever is longer) before screening, and are expected to take any medication during the study period (except for the rosuvastatin treatment in Part C) (excluding treatment for adverse events).
  13. Subjects with diseases or conditions that, as determined by the investigator, could significantly affect the absorption of drugs or nutrients, such as clinically significant gastrointestinal diseases (e.g., active inflammatory bowel disease) or symptoms of gastrointestinal disorders; or any condition that could affect drug absorption, such as subtotal or total gastrectomy, gastric bypass, or any bowel resection.
  14. Subjects whom the investigator deems ineligible.

    Subjects with the following diseases or medical history before screening or before randomization:

  15. Subjects with a history of severe allergy/ or ongoing clinically significant allergy/hypersensitivity, or a history of hypersensitivity to drugs with a chemical structure similar to HS-10510, as determined by the investigator.
  16. Subjects with a history of endocrine diseases that could significantly affect body weight, such as diabetes, Cushing's syndrome, hypothyroidism, or hyperthyroidism.
  17. Subjects with a history of moderate to severe depression or a history of severe psychiatric disorders, such as schizophrenia or bipolar disorder.
  18. Subjects with a history of acute or chronic hepatitis or other severe liver diseases, except for non-alcoholic fatty liver disease.
  19. Subjects with a history of severe cardiovascular disease within 6 months before screening, including decompensated heart failure ( class III and IV), unstable angina, stroke or , acute myocardial infarction, severe arrhythmia, or coronary artery bypass grafting or percutaneous coronary intervention.
  20. Subjects with a history of or current severe infection, such as cellulitis, pneumonia, or sepsis, within 30 days before screening.
  21. Subjects with a history of drug abuse or illicit drug use within 1 year before screening, or positive results on urine drug screening.
  22. Subjects with a history of alcoholism or who have consumed more than 14 units of alcohol (1 unit = 285 mL of beer, 25 mL of spirits (≥35% alcohol), 150 mL of wine) in a single session within 2 weeks before screening, or positive results on alcohol breath testing at screening.
  23. Subjects with a history of malignant tumors.
  24. Subjects who have received or plan to receive live (attenuated) vaccines within 12 weeks before screening.
  25. Subjects with concurrent cardiovascular, liver, kidney, gastrointestinal, psychiatric, neurological, hematological, or metabolic disorders.

    Subjects who have used any of the following medications or treatments before screening:

  26. Subjects who have used medications that could affect cholesterol levels (e.g., statins, ezetimibe, niacin, and supplements such as ω-3 fatty acids) within 8 weeks before screening.
  27. Subjects who are currently or have previously received inclisiran sodium or other siRNA PCSK9 inhibitors.
  28. Subjects who have received PCSK9 inhibition (approved or investigational) treatment within 12 months before screening.
  29. Subjects who have received microsomal triglyceride transfer protein inhibitors (e.g., lomitapide) within 12 months before screening.
  30. Subjects who have received systemic therapy, immunomodulatory therapy, or chemotherapy within 3 months before screening, or who may receive these treatments during the study period.
  31. Subjects who are currently receiving or have received medications known to prolong the QT interval (refer to the package insert) within 14 days before screening.

    Subjects with any of the following conditions:

  32. Subjects who have participated in any drug or medical device clinical trial and received at least one treatment (including placebo) within 12 weeks before screening, or are still within 5 half-lives of the investigational drug (whichever is longer, excluding those who did not receive the investigational drug or device).
  33. Subjects who are strict vegetarians or have medical dietary restrictions.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
88 participants (estimated)

Study arms

  • Active comparator
    Part A-HS-10510 dose 1/placebo

    A total of 6 subjects will receive single ascending doses of HS-10510 and 2 will receive placebo

    Drug: Drug:HS-10510; · Drug: Drug:Placebo

  • Active comparator
    Part A-HS-10510 dose 2/placebo

    A total of 6 subjects will receive single ascending doses of HS-10510 and 2 will receive placebo

    Drug: Drug:HS-10510; · Drug: Drug:Placebo

  • Active comparator
    Part A-S-10510 dose 3/placebo

    A total of 6 subjects will receive single ascending doses of HS-10510 and 2 will receive placebo

    Drug: Drug:HS-10510; · Drug: Drug:Placebo

  • Active comparator
    Part A-HS-10510 dose 4/placebo

    A total of 6 subjects will receive single ascending doses of HS-10510 and 2 will receive placebo

    Drug: Drug:HS-10510; · Drug: Drug:Placebo

  • Active comparator
    Part B-HS-10510 dose 1/placebo

    A total of 9 subjects will receive multiple ascending doses of HS-10510 and 3 will receive placebo

    Drug: Drug:HS-10510; · Drug: Drug:Placebo

  • Active comparator
    Part B-HS-10510 dose 2/placebo

    A total of 9 subjects will receive multiple ascending doses of HS-10510 and 3 will receive placebo

    Drug: Drug:HS-10510; · Drug: Drug:Placebo

  • Active comparator
    Part B-HS-10510 dose 3/placebo

    A total of 9 subjects will receive multiple ascending doses of HS-10510 and 3 will receive placebo

    Drug: Drug:HS-10510; · Drug: Drug:Placebo

  • Active comparator
    Part C-HS-10510/Placebo with rosuvastatin

    A total of 10 subjects will receive HS-10510 in combination with rosuvastatin and 10 subjects will receive placebo in combination with rosuvastatin

    Drug: Drug:HS-10510; · Drug: Drug:Placebo · Drug: Drug: Rosuvastatin

Interventions

  • DrugDrug:HS-10510;

    Drug:HS-10510 Description:Subjects will receive HS-10510 orally as a single and multiple ascending dose.

  • DrugDrug:Placebo

    Drug:Placebo Description:Subjects will receive placebo matching the HS-10510 dose orally as a single and multiple ascending dose.

  • DrugDrug: Rosuvastatin

    Drug:Rosuvastatin Description:Subjects will receive rosuvastatin orally.

06

What researchers measure

Primary outcomes

  1. Number of subjects with Adverse Events

    The safety and tolerability of HS-10510 following oral administration of single ascending doses (Part A) and multiple ascending doses (Part B and C) will be assessed.

    Time frame: From Screening until Follow-up Visit (7 days post-dose for all cohorts)

Secondary outcomes

  1. LDL-C

    The pharmacodynamics (PD) of HS-10510 by assessment of LDL-C following oral administration of single ascending doses (Part A) and multiple ascending doses (Part B and C) will be assessed.

    Time frame: SAD cohorts: Days 1,2,3,4,8 Food Effect SAD cohort: Day 1,2,3,4,8,9,10,11,15 MAD cohorts: Days1,2,3,4,7,11,15,22,26,28,31,35 Rosuvastatin MAD Cohorts: Days1,2,3,4,7,11,15,22,26,28,31,35

  2. Proprotein convertase subtilisin/kexin type 9(PCSK9)

    The PD of HS-10510 by assessment of PCSK9 following oral administration of single ascending doses (Part A) and multiple ascending doses (Part B and C) will be assessed.

    Time frame: SAD cohorts: Days 1,2,3,8 Food Effect SAD cohort: Day 1,2,3,8,9,10,15 MAD cohorts: Days 1,2,3,7,11,15,22,28,31,35 Rosuvastatin MAD Cohorts: Days 1,2,3,7,11,15,22,28,31,35

  3. HS-10510 PK parameter: Maximum observed plasma concentration (Cmax)

    To characterise the single dose and steady state PK of HS-10510 following oral administration of HS-10510.

    Time frame: SAD cohorts: Day 1 to Day 4 Food Effect SAD cohort: Day 1 to Day 4 and Day 8 to Day 11 MAD cohorts: Day 1 to Day 31 Rosuvastatin MAD Cohorts: Day 1 to Day 31

  4. HS-10510 PK parameter: Area under plasma concentration-time curve from zero to infinity (AUC0-inf)

    To characterise the single dose and steady state PK of HS-10510 following oral administration of HS-10510.

    Time frame: SAD cohorts: Day 1 to Day 4 Food Effect SAD cohort: Day 1 to Day 4 and Day 8 to Day 11 MAD cohorts: Day 1 to Day 31 Rosuvastatin MAD Cohorts: Day 1 to Day 31

  5. HS-10510 PK parameter: Area under the plasma concentration-curve from 0 to the last quantifiable concentration (AUC0-last)

    To characterise the single dose and steady state PK of HS-10510 following oral administration of HS-10510.

    Time frame: SAD cohorts: Day 1 to Day 4 Food Effect SAD cohort: Day 1 to Day 4 and Day 8 to Day 11 MAD cohorts: Day 1 to Day 31 Rosuvastatin MAD Cohorts: Day 1 to Day 31

  6. HS-10510 PK parameter: Area under the plasma concentration-curve across the dosing interval (AUC0-tau)

    To characterise the steady state PK of HS-10510 following oral multiple administration of HS-10510.

    Time frame: MAD cohorts: Day 1 to Day 31 Rosuvastatin MAD Cohorts: Day 1 to Day 31

  7. HS-10510 PK parameter: Time to reach maximum observed concentration (Tmax)

    To characterise the single dose and steady state PK of HS-10510 following oral administration of HS-10510.

    Time frame: SAD cohorts: Day 1 to Day 4 Food Effect SAD cohort: Day 1 to Day 4 and Day 8 to Day 11 MAD cohorts: Day 1 to Day 31 Rosuvastatin MAD Cohorts: Day 1 to Day 31

  8. HS-10510 PK parameter: Terminal elimination half-life (t½)

    To characterise the single dose and steady state PK of HS-10510 following oral administration of HS-10510.

    Time frame: SAD cohorts: Day 1 to Day 4 Food Effect SAD cohort: Day 1 to Day 4 and Day 8 to Day 11 MAD cohorts: Day 1 to Day 31 Rosuvastatin MAD Cohorts: Day 1 to Day 31

  9. HS-10510 PK parameter: Apparent total body clearance (CL/F)

    To characterise the single dose and steady state PK of HS-10510 following oral administration of HS-10510.

    Time frame: SAD cohorts: Day 1 to Day 4 Food Effect SAD cohort: Day 1 to Day 4 and Day 8 to Day 11 MAD cohorts: Day 1 to Day 31 Rosuvastatin MAD Cohorts: Day 1 to Day 31

  10. HS-10510 PK parameter: Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)

    To characterise the single dose and steady state PK of HS-10510 following oral administration of HS-10510.

    Time frame: SAD cohorts: Day 1 to Day 4 Food Effect SAD cohort: Day 1 to Day 4 and Day 8 to Day 11 MAD cohorts: Day 1 to Day 31 Rosuvastatin MAD Cohorts: Day 1 to Day 31

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2025; primary completion for Feb 2026, 8 months later.

Of 77 industry-sponsored phase 1 interventional studies under Dyslipidemias, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's planned 8 months is above that.

Counting every sponsor, half of 83 studies reached it within 2 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2025
First posted
Jun 3, 2025
StartEst.
Jun 2025
Primary completionEst.
Feb 2026
CompletionEst.
Mar 2026
Last update
Jun 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07001787
Responsible party
Sponsor
First posted
Jun 3, 2025
Start date
Jun 2025 (estimated)
Primary completion
Feb 2026 (estimated)
Completion
Mar 2026 (estimated)
Last update
Jun 3, 2025

Study contacts

Haiyan Li Director of Institution for Drug Trials
Contact
haiyanli1027@hotmail.com
010-68966677-8508
Fangfang Wang NA
Contact
doctorfancy@126.com
010-68966677-8508

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion